

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Bellus Health (International) Limited	03/29/2011
RECEIVING PARTY DATA	
Name:	Bellus Health Inc.
Street Address:	275 Armand-Frappier Boulevard
City:	Laval, Quebec
State/Country:	CANADA
Postal Code:	H7V 4A7
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	12362971
Application Number:	11103656
CORRESPONDENCE DATA	
Fax Number:	(703)243-6410
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	7032436333
Email:	kbrown@mwzb.com
Correspondent Name:	Millen, White, Zelano & Branigan, P.C.
Address Line 1:	2200 Clarendon Boulevard
Address Line 2:	Suite 1400
Address Line 4:	Arlington, VIRGINIA 22201
ATTORNEY DOCKET NUMBER:	BELLUS-0003-A-C01
NAME OF SUBMITTER:	Anthony J. Zelano
Total Attachments: 3 source=Assignment-07June2011#page1.tif source=Assignment-07June2011#page2.tif source=Assignment-07June2011#page3.tif	

OP \$80.00 12362971

501556525

PATENT
REEL: 026400 FRAME: 0132

ASSIGNMENT

BELLUS HEALTH (INTERNATIONAL) LIMITED, in liquidation, a Corporation organized under the laws of Switzerland, having its principal place of business at PSE-Parc Scientifique sur le site de l'Ecole Polytechnique Fédérale de Lausanne à Ecublens, CH-1015 Lausanne, Switzerland, (the "Assignor") in consideration of valuable consideration paid to it by

BELLUS HEALTH INC.

a Corporation organized under the Canada Business Corporations Act, having its principal place of business at 275 Armand-Frappier Boulevard, Laval, Québec, H7V 4A7, Canada, the receipt of which is hereby acknowledged, does hereby sell, assign and transfer unto said

BELLUS HEALTH INC.

its successors and assigns (collectively the "Assignee"), the entire interest for Canada, the United States of America, and all foreign countries in certain invention(s) or improvement(s) described in the Patents and Applications listed in Schedule A, including all rights of priority under the International Convention for the Protection of Industrial Property, in any Patent Office, and in all Letters Patent of any country which may or shall be granted on said invention, or any parts thereof, or on said application, or any divisional, continuation, continuation-in-part, reexamination, reissue, national phase, regional phase, validation, or other applications or patents based in whole or in part thereon, the same to be held and enjoyed by the Assignee, for its own use and benefit and the use and benefit of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent may be granted or extended, as fully and entirely as the same would have been held and enjoyed by the Assignor had this assignment not been made. And the Assignor agrees, for itself and its successors and assigns, with the Assignee and its successors and assigns but at its or their expense and charges, hereafter to execute all applications, amended specifications, deed or other instrument, and to do all acts necessary or proper to secure the grant of Letters Patent in the United States and in all other countries to the Assignee, with specifications and claims in such form as shall be approved by the counsel of said Assignee and to vest and confirm in the Assignee the legal title to all such patents.

And the Assignor does hereby authorize and request the Commissioner of Patents and Trademarks of the United States and all other Patents Offices to issue such Letters Patent as shall be granted upon said application or applications based thereon to the Assignee.

On behalf of BELLUS HEALTH (INTERNATIONAL) LIMITED, in liquidation:


Date: March 29, 2011



Name: Jeannine Huck
Title: Liquidator

Witness:


Date: March 29, 2011



Name: Ralph Schmid

On behalf of BELLUS HEALTH INC.:


Date: March 29, 2011



Name: François Desjardins
Title: Vice-president, Finance

Witness:

Date: March 29, 2011



Name: NANCY BARRIAULT

Date: March 29, 2011



Name: Roberto Bellini
Title: President and Chief Executive Officer

Witness:

Date: March 29, 2011



Name: NANCY BARRIAULT

SCHEDULE A

030: Pharmaceutical Formulations of Amyloid-Inhibiting Compounds

Country	Patent/Application No.
U.S.A.	60/480,984
U.S.A.	60/512,116
U.S.A.	10/871,549
U.S.A.	60/640,108
U.S.A.	11/103,656
U.S.A.	12/362,971
PCT	PCT/IB2004/002381
Australia	2004248995
Australia	2010201299
Brazil	PI0411808-1
Canada	2,529,268
China	200480024244.8
Europe	1635799
Austria	1635799
Belgium	1635799
Switzerland	1635799
Czech Republic	1635799
Germany	602004022408.1-08
Denmark	1635799
Spain	1635799
Finland	1635799
France	1635799
United Kingdom	1635799
Greece	1635799
Hungary	1635799
Ireland	1635799
Italy	1635799
Luxembourg	1635799
Monaco	1635799
Netherlands	1635799
Poland	1635799
Portugal	1635799
Romania	1635799
Sweden	1635799
Slovenia	1635799
Slovak Republic	1635799
Turkey	2009 07634 T4
Europe	09009983.9
Hong Kong	07101022.3
Hong Kong	10104348.9
Israel	172193
India	234091
India	262/CHENP/2009
Japan	2006-516600
Mexico	267678
Mexico	MX/a/2009/006666
New Zealand	544685